SCHEMBL10824813

SCHEMBL10824813

Cn1cncc1C(=O)Nc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.54
KDM1A O60341 3/20 0.49
RCOR1 Q9UKL0 3/20 0.49
NAMPT P43490 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.47
NPC1 O15118 3/20 0.46
TP53 P04637 1/20 0.46
PRMT5 O14744 3/20 0.46
WDR77 Q9BQA1 3/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31022619 0.86 NAMPT (0.66) RAB9AKDM1ARCOR1NAMPTSMN1; SMN2
SCHEMBL31650535 0.83 ALDH1A1 (0.51) NAMPTSMN1; SMN2ALDH1A1PRMT5WDR77
SCHEMBL2514323 0.83 NAMPT (0.42) RAB9AKDM1ARCOR1NAMPTSMN1; SMN2
SCHEMBL31650777 0.80 NAMPT (0.54) RAB9ANAMPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL9199617 0.79 ATM (0.51) RAB9ASMN1; SMN2HTTNPC1MEN1
SCHEMBL20854623 0.79 SNCA (0.46) RAB9ANAMPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL23406103 0.79 PTPN2 (0.46) RAB9ANAMPTSMN1; SMN2ALDH1A1HTT
SCHEMBL20653377 0.79 HPGDS (0.44) RAB9AALDH1A1HTTNPC1TP53
SCHEMBL31650395 0.79 SMN1; SMN2 (0.64) RAB9ASMN1; SMN2ALDH1A1HTTNPC1
SCHEMBL20741592 0.77 MCHR1 (0.48) RAB9APRMT5WDR77KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-61178968-A None JP disclosed
US-20230183213-A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. 2023-06-15 US disclosed
JP-S61178968-A PRODUCTION OF 1-SUBSTITUTED IMIDAZOLE-5-CARBOXAMIDE DERIVATIVE NIPPON CARBIDE IND CO LTD 1986-08-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183213-A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV HCCS, HAVCR2, MAVS RAB9A 1662/4885KDM1A 2772/4885RCOR1 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.